Statin therapy in Canadian patients with hypercholesterolemia: The Canadian Lipid Study - Observational (CALIPSO)

Canadian Journal of Cardiology

Volumn 21, Issue 13, 2005, Pages 1187-1193

  Bourgault, Chantal ^a,b,j   Davignon, Jean ^c   Fodor, George ^d   Gagné, Claude ^e   Gaudet, Daniel ^f   Genest, Jacques ^b   Lavoie, Marc André ^f   Leiter, Lawrence ^g   McPherson, Ruth ^a   Sénécal, Martin ^a   Marentette, Michael ^a   Sebaldt, Rolf J ^h,i  

^a MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^d UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^e UNIVERSITÉ LAVAL   (Canada)

^f MONTREAL HEART INSTITUTE   (Canada)

^g ST MICHAEL'S HOSPITAL   (Canada)

^h FigP Software Incorporated   (Canada)

ⁱ MCMASTER UNIVERSITY   (Canada)

^j McMaster University ^*  (Canada)

more..

Author keywords

Drugs; Epidemiology; Hypercholesterolemia; Lipoproteins

Indexed keywords

ATORVASTATIN; EZETIMIBE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADOLESCENT; ADULT; ARTICLE; CANADA; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COMORBIDITY; DRUG COST; DRUG DOSE REGIMEN; FEMALE; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PATIENT MONITORING; PRACTICE GUIDELINE; RISK REDUCTION; SIDE EFFECT; TREATMENT OUTCOME;

AGED; CANADA; CHOLESTEROL, LDL; COMORBIDITY; CORONARY DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; GUIDELINE ADHERENCE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; RISK FACTORS;

EID: 29544448092     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Heart and Stroke Foundation of Canada. The Growing Burden of Heart Disease and Stroke in Canada 2003. Ottawa: Heart and Stroke Foundation of Canada, 2003.
2. Choi BK, Pak AW. A method for comparing and combining cost-of-illness studies: An example from cardiovascular disease. Chronic Dis Can 2002;23:47-57.
3. D'Agostino RB, Russell MW, Huse DM, et al. Primary and subsequent coronary risk appraisal: New results from the Framingham study. Am Heart J 2000;139:272-81.
4. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit: Impact of statin trials. Circulation 1998;97:946-52.
5. Genest J, Frohlich J, Fodor G, McPherson R. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: Summary of the 2003 update. CMAJ 2003;169:921-4.
6. MacLean DR, Petrasovits A, Connelly PW, et al. Plasma lipids and lipoprotein reference values, and the prevalence of dyslipoproteinemia in Canadian adults. Canadian Heart Health Surveys Research Group. Can J Cardiol 1999; 15:434-44.
7. Langille DB, Joffres MR, MacPherson KM, Andreou P, Kirkland SA, MacLean DR. Prevalence of risk factors for cardiovascular disease in Canadians 55 to 74 years of age: Results from the Canadian Heart Health Surveys, 1986-1992. CMAJ 1999;161(8 Suppl):S3-9.
8. Ramsay LE, Yeo WW, Jackson PR. Dietary reduction of serum cholesterol concentration: Time to think again. BMJ 1991;303:953-7.
9. Hunninghake DB, Stein EA, Dujovne CA, et al. The efficacy of intensive dietary therapy alone or combined with lovastatin in outpatients with hypercholesterolemia. N Engl J Med 1993;328:1213-9.
10. Jacobson TA. Clinical context: Current concepts of coronary heart disease management. Am J Med 2001;110(Suppl 6A):3S-11S.
11. Davidson MH. Combination therapy for dyslipidemia: Safety and regulatory considerations, Am J Cardiol 2002;90:50K-60K.
12. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: Systematic review and meta-analysis. Br Med J 2003;326:1423-9.
13. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96.
14. Fodor JG, Frohlich JJ, Genest JJ, McPherson PR. Recommendations for the management and treatment of dyslipidemia. Report of the Working Group on Hypercholesterolemia and Other Dyslipidemias. CMAJ 2000;162:1441-7.
15. Grundy SM, Pasternak R, Greenland P, Smith S Jr, Fuster V. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 1999;100:1481-92.
16. Goettsch WG, Yin DD, Alemao E, et al. Statins are less effective in common daily practice among patients with hypercholesterolemia: The REALITY-PHARMO study. Curr Med Res Opin 2004;20:1025-33.
17. Pearson TA, Lamora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459-67.
18. Svilaas A, Risberg K, Thoresen M, Ose L. Lipid treatment goals achieved in patients treated with statin drugs in Norwegian general practice. Am J Cardiol 2000;86:1250-3, A6.
19. EUROASPIRE I and II Group. Clinical reality of coronary prevention guidelines: A comparison of EUROASPIRE I and II in nine countries. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet 2001;357:995-1001.
20. Vale MJ, Jelinek MV, Best JD. How many patients with coronary heart disease are not achieving their risk-factor targets? Experience in Victoria 1996-1998 versus 1999-2000. Med J Aust 2002;176:211-5.
21. Olson KL, Bungard TJ, Tsuyuki RT. Cholesterol risk management: A systematic examination of the gap from evidence to practice. Pharmacotherapy 2001;21:807-17.
22. Frolkis JP, Pearce GL, Nambi V, Minor S, Sprecher DL. Statins do not meet expectations for lowering low-density lipoprotein cholesterol levels when used in clinical practice. Am J Med 2002;113:625-9.
23. Tsuyuki RT, Bungard TJ. Poor adherence with hypolipidemic drugs: A lost opportunity. Pharmacotherapy 2001;21:576-82.
24. McKenney J. Combination therapy for elevated low-density lipoprotein cholesterol: The key to coronary artery disease risk reduction. Am J Cardiol 2002;90:8K-20K.
25. Grundy SM. Alternative approaches to cholesterol-lowering therapy. Am J Cardiol 2002;90:1135-8.
26. Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999;341:498-511.
27. Andrews TC, Ballantyne CM, Hsia JA, Kramer JH. Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins. Am J Med 2001;111:185-91.
28. Stein EA. Managing dyslipidemia in the high-risk patient. Am J Cardiol 2002;89:50C-7C.
29. Stein E. The lower the better? Reviewing the evidence for more aggressive cholesterol reduction and goal attainment. Atheroscler Suppl 2002;2:19-23.
30. Dorval JF, Anderson T, Buithieu J, et al. Reaching recommended lipid and blood pressure targets with amlodipine/atorvastatin combination in patients with coronary heart disease. Am J Cardiot 2005;95:249-53.
31. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39.
32. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35.